US › Healthcare

Biodexa Pharmaceticals (BDRX)

US · Healthcare · Biotechnology

$1.49+4.93%
Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Net profit
$-2.6M
Profit YoY
+22.5%
EPS
$-15.06
EPS estimate
$0.00

Key statistics

Market cap
$1.3M
Forward P/E
0.0
P/B
0.08
Book value
$34.04
EPS (TTM)
$-3.37
52-week high
$59.40
52-week low
$1.02
50-day MA
$2.67
200-day MA
$10.77
Beta
1.21

Analyst view

Analysts rate Biodexa Pharmaceticals a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $10.07.

Shareholding

Institutions
9.19%

Largest institutional holders

FundStake
Sabby Management LLC11.40%
Armistice Capital, LLC4.32%
GAMMA Investing LLC0.27%
Allied Private Wealth LLC0.11%
SBI Securities Co Ltd0.01%
UBS Group AG0.01%
Hilton Head Capital Partners, LLC0.00%
Rhumbline Advisers0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Biodexa Pharmaceticals — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.